The Endocrinology Society has announced that the Apitope paper published in Endocrinology entitled “Immunotherapy With Apitopes Blocks the Immune Response to TSH Receptor in HLA-DR Transgenic Mice” has been featured in its Thematic issue on immuno endocrinology. The paper was recognised for its high Altmetric Attention Score and Featured Article designations.
The Endocrine Society said “We appreciate your cutting-edge, influential contributions to the endocrine community and are delighted to promote it in our thematic collection”
Apitope’s Chief Executive Officer Hayley French and Chief Research Officer Lotta Jansson will be attending JP Morgan 38th Annual Healthcare Conference 13-16 January 2020 in San Francisco.
Please contact Hayley.French@apitope.com or Lotta.Jansson@apitope.com for further information
Apitope’s Antigen specific immunotherapy for Graves’ disease features in the October 2019 edition of the British Thyroid Foundation Newsletter (BTF) and the article is also available on the BTF website by following this link: https://www.btf-thyroid.org/research-news-graves-disease
HASSELT, Belgium, and CHEPSTOW, UK, 13 September 19 – Apitope, a clinical stage biotech company developing potential first-in-class antigen-specific immunotherapies targeting autoimmune diseases, today announces that the first in human clinical trial for the treatment of Graves’ disease funded by the European Union (DAVIAD) has been published as a “Success Story” on the European Union website. The article entitled ‘ New treatment on the horizon for Graves’ disease’ can be viewed in the following link:
Professor David Wraith Apitope’s co-founder and CSO will present as an invited speaker at the 18th International Celiac Disease Symposium ICDS. The conference is being held between 5th and 11th September at the Marriott Rive Gauche in Paris.
Professor David Wraith Apitope’s founder and CSO and Dr Lotta Jansson, Chief Research Officer are scheduled to attend ECTRIMS 2019. The conference is being held in Stockholm Sweden between 11th-13th September ECTRIMS 2019 at the Stockholmsmässan.
Professor Wraith will present during Session 12 entitled ‘Immunopathogenesis and antigen specific therapies’ details of which are below:
13 September 2019
Presentation: A future for antigen specific immunotherapy for multiple sclerosis
Presenter: David Wraith
Professor David Wraith Apitope’s co-founder and CSO will present as an invited speaker at Immunity for Health 2019. The conference theme is Therapeutic Vaccines & Immunotherapy and is being held University Hasselt, Belgium on 15th October 2019.
15 October 2019
Key Note Presentation: The Future of Immunotherapy: A 20-Year Perspective
Presenter: David Wraith
Professor David Wraith Apitope’s co-founder and CSO will present as an invited speaker at the 40th Annual Meeting, 17-20 November, 2019, at the JW Marriott Desert Ridge in Phoenix, Arizona.
Professor Wraith will present during Session 10 entitled ‘Immune Tolerance: State-of-the-Science and Preclinical and Clinical Safety Challenges in Drug Development’:
19 November 2019
Presentation: State-of-Science of Immune Tolerance, and Trending Therapeutic Concepts for New and Differentiated Mechanisms of Action
Presenter: David Wraith
HASSELT, Belgium, and CHEPSTOW, UK, 20 June 19 – Apitope, a clinical stage biotech company developing potential first-in-class antigen-specific immunotherapies targeting autoimmune diseases, today announces publication of its clinical Graves’ disease data in Thyroid, one of the leading peer-reviewed thyroid disease related medical journals.
The publication entitled: Antigen-Specific Immunotherapy with Thyrotropin Receptor Peptides in Graves’ Hyperthyroidism: A Phase I Study , reports the results from a first in human clinical study to assess the safety, tolerability and efficacy of Apitope’s antigen-specific immunotherapy, ATX-GD-59, in patients with Graves’ disease.
The open-label trial reported in the paper was conducted in patients with mild to moderate Graves’ disease. These preliminary data suggest that ATX-GD-59 is a safe and well-tolerated treatment. The improvement in free thyroid function in 70% of subjects receiving the medication suggests potential efficacy as a novel treatment for Graves’ hyperthyroidism.
Hayley French, CEO of Apitope, said: “We are delighted that these data have been published in Thyroid, a peer-reviewed journal for thyroid related diseases. For people suffering from Graves’, the project’s progress has finally created hope that the underlying disease can be treated and, for the first time in over 70 years, an innovative disease modifying treatment could be on the horizon”.
Apitope’s Chief Executive Officer, Dr Hayley French will be attending the BIO 2019 conference to be held on 3-6 June 2019 in Philadelphia, PA